From known drugs
to better therapies
Galenicap transforms known drug substances into clinically differentiated therapies by combining scientific insight, clinical relevance, and a scalable development model.
Who we are
Galenicap is a pharmaceutical development company founded in 2022 and operating across Belgium and the Netherlands. We focus on developing improved therapies from existing drug molecules, leveraging deep pharmaceutical expertise and clinical understanding to create new therapeutic opportunities with clear medical and commercial value.
What we build
We design new medicines by improving how known compounds are delivered, positioned, and used in clinical practice. Each program is built to enhance therapeutic performance and address meaningful gaps in patient care, while creating differentiated assets with strong intellectual property and well-defined development pathways.
Our model
Our approach is based on a structured and repeatable model for clinical asset creation. By starting from compounds with established safety and validated biology, we reduce early-stage risk and focus on generating differentiation where it matters most. This enables efficient progression toward clinical proof of concept and strategic partnering or exit.
Why it matters
By operating between traditional drug discovery and generic development, Galenicap combines scientific rigor with capital efficiency. Our model allows us to deliver therapies that improve patient outcomes while creating scalable value through a growing portfolio of high-potential programs.